Tolebrutinib not superior to teriflunomide in reducing relapsing multiple sclerosis relapse rates
1. In concurrent randomized controlled trials (GEMINI 1 and GEMINI 2) of patients with relapsing multiple sclerosis (RMS), tolebrutinib did ...
1. In concurrent randomized controlled trials (GEMINI 1 and GEMINI 2) of patients with relapsing multiple sclerosis (RMS), tolebrutinib did ...
Click here to read this study in NEJM. ©2025 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
1. Two randomized clinical trials showed that intravenous ublituximab reduced relapse rate and the number of brain lesions in multiple ...
1. In this double-blind, randomized phase 3 trial, patient treated with ofatumumab had a lower annualized relapse rate in multiple ...
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.